With the recent approval of the first pill for postpartum depression, I feel conflicted, both professionally and personally.
Unfortunately, up to 50% of women with postpartum depression go undiagnosed.
A first-of-its-kind medication hits the marketRecently, the US Food and Drug Administration approved the first pill for severe postpartum depression, Zurzuvae (zuranolone).
It may even empower clinicians to screen more often for postpartum depression, knowing there’s a potential tool to help people if they do screen positive.
The worst part is that mothers living in poverty generally show higher rates of postpartum depression than those from higher-income communities.
Persons:
Neha Chaudhary, it’s, there’s, I’m
Organizations:
Massachusetts General Hospital, Harvard Medical School, Modern Health, CNN, US Food and Drug Administration
Locations:
Massachusetts